We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.
Filters applied:

Search Results

Showing 1-20 of 4,005 results
  1. CYX-5, a G-protein biassed MOP receptor agonist, DOP receptor antagonist and KOP receptor agonist, evokes constipation but not respiratory depression relative to morphine in rats

    Background

    Strong opioid analgesics such as morphine alleviate moderate to severe acute nociceptive pain (e.g. post-surgical or post-trauma pain) as...

    Mohammad Zafar Imam, Andy Kuo, ... Maree T. Smith in Pharmacological Reports
    Article Open access 13 January 2023
  2. Effect of the Topical External Formulation of the Low-Affinity NMDA Receptor Antagonist Hemantane on Peripheral Sensitization Induced by TRPV1 Receptor Agonist Capsaicin in Mice

    The effect of the noncompetitive low-affinity NMDA receptor antagonist hemantane [ N -(2-adamantyl)hexamethyleneimine hydrochloride) in two topical...

    E. A. Ivanova, A. I. Matyushkin, T. A. Voronina in Pharmaceutical Chemistry Journal
    Article 11 February 2022
  3. The Role of a Dopaminergic Component in the Analgesic Effect of the Low-Affinity NMDA Receptor Antagonist Hemantane

    The role of dopaminergic transmission in the mechanism of analgesic action of the low-affinity NMDAreceptor antagonist hemantane [ N -(2-adamantyl)hexam...

    E. A. Ivanova, I. G. Kapitsa, T. A. Voronina in Pharmaceutical Chemistry Journal
    Article 11 January 2021
  4. NMDA-Receptor Antagonists Reduce Skin Sensitivity to the TRPV1-Receptor Agonist Capsaicin

    Glutamate receptors are widely represented in the central and peripheral nervous systems, which determines their involvement in central and...

    E. A. Ivanova, A. I. Matyushkin, T. A. Voronina in Pharmaceutical Chemistry Journal
    Article 01 December 2021
  5. Novel object recognition test as an alternative approach to assessing the pharmacological profile of sigma-1 receptor ligands

    Background

    Although the terms “agonist” and “antagonist” have been used to classify sigma-1 receptor (σ 1 R) ligands, an unambiguous definition of the...

    Katarzyna Szczepańska, Andrzej J. Bojarski, ... Natalia Malikowska-Racia in Pharmacological Reports
    Article Open access 12 August 2023
  6. Physicochemical Properties of a Phenyltetrahydroquinolinedione Derivative with TRPA1 Antagonist Activity

    A new active pharmaceutical ingredient (API) with TRPA1-antagonist activity (phenyltetrahydroquinolinedione derivative) was a white or almost white...

    N. V. Pyatigorskaya, N. S. Nikolenko, A. D. Kravchenko in Pharmaceutical Chemistry Journal
    Article 09 July 2022
  7. Synthesis and Adenosine RA1/A2A Receptor Affinity of Selected Aurones and 2-Benzylidene-1-Indanones

    In the search to discover new adenosine A 1 /A 2A receptor ligands, ten aurones (2-benzylidenebenzofuran-3(2H)-ones) and 2-benzylidene-1-indanones were...

    Helena D. Janse van Rensburg, Gisella Terre’Blanche, Lesetja J. Legoabe in Pharmaceutical Chemistry Journal
    Article 01 August 2023
  8. Clinical Efficacy of Long-Acting β2 Agonists and Long-Acting Muscarinic Antagonist for Moderate to Severe Chronic Obstructive Pulmonary Disease

    We have studied the clinical efficacy of long-acting β2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) for the treatment of moderate to...

    Yongqian Xu, Yu Pang in Pharmaceutical Chemistry Journal
    Article 21 June 2023
  9. The novel psychoactive substance 25E-NBOMe induces reward-related behaviors via dopamine D1 receptor signaling in male rodents

    Novel psychoactive substances (NPSs) are new psychotropic drugs designed to evade substance regulatory policies. 25E-NBOMe...

    Young-Jung Kim, Wun-A Kook, ... Choon-Gon Jang in Archives of Pharmacal Research
    Article 29 March 2024
  10. Soluble dipeptidyl peptidase-4 induces epithelial–mesenchymal transition through tumor growth factor-β receptor

    Background

    Kidney fibrosis is the final manifestation of chronic kidney disease, a condition mainly caused by diabetic nephropathy. Persistent tissue...

    Cheng-Wei Huang, Shih-Yi Lee, ... Hui-Chun Ku in Pharmacological Reports
    Article 26 May 2023
  11. Evaluation of the effects of the mGlu2/3 antagonist LY341495 on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset

    Background

    We have previously demonstrated that the metabotropic glutamate 2 and 3 (mGlu 2/3 ) antagonist LY341495 reverses the anti-dyskinetic and...

    Stephen G. Nuara, Jim C. Gourdon, Philippe Huot in Pharmacological Reports
    Article 27 June 2022
  12. The role of GPR39 zinc receptor in the modulation of glutamatergic and GABAergic transmission

    Background

    Despite our poor understanding of the pathophysiology of depression, a growing body of evidence indicates the role of both glutamate and...

    Gabriela Starowicz, Dominika Siodłak, ... Katarzyna Mlyniec in Pharmacological Reports
    Article Open access 30 March 2023
  13. Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies

    The desire to find a gold-standard therapy for depression is still ongoing. Develo** one universal and effective pharmacotherapy remains...

    Barbara Chruścicka-Smaga, Agata Machaczka, ... Andrzej Pilc in Pharmacological Reports
    Article Open access 07 November 2023
  14. Evaluation of the 5-HT2C receptor drugs RO 60-0175, WAY 161503 and mirtazepine in a preclinical model of comorbidity of depression and cocaine addiction

    Background

    Epidemiological data indicate a high rate of comorbidity of depression and cocaine use disorder (CUD). The role of serotonin 2C (5-HT 2C )...

    Joanna Jastrzębska, Małgorzata Frankowska, ... Małgorzata Filip in Pharmacological Reports
    Article Open access 14 November 2022
  15. Partial mGlu5 receptor NAM, M-5MPEP, induces rapid and sustained antidepressant-like effects in the BDNF-dependent mechanism and enhances (R)-ketamine action in mice

    Background

    Partial negative allosteric modulators (NAM) of the metabotropic glutamate 5 (mGlu 5 ) receptor are an excellent alternative to full...

    Agnieszka Pałucha-Poniewiera, Anna Rafało-Ulińska, ... Katarzyna Kaczorowska in Pharmacological Reports
    Article 18 April 2024
  16. Escitalopram alters local expression of noncanonical stress-related neuropeptides in the rat brain via NPS receptor signaling

    Background

    Neuropeptide S (NPS) is a multifunctional regulatory factor that exhibits a potent anxiolytic activity in animal models. However, there are...

    Aneta Piwowarczyk-Nowak, Artur Pałasz, ... John J. Worthington in Pharmacological Reports
    Article 02 June 2022
  17. Search for Selective Glua1 Ampa Receptor Antagonists in a Series of Dicationic Compounds

    Homologous series of dicationic derivatives based on adamantyl and phenylcyclohexyl fragments in which the cationic groups and the distance between...

    V. E. Gmiro, A. S. Zhigulin in Pharmaceutical Chemistry Journal
    Article 26 May 2022
  18. Reduction of the serotonin 5-HT1B and 5-HT2A receptor-mediated contraction of human pulmonary artery by the combined 5-HT1B receptor antagonist and serotonin transporter inhibitor LY393558

    Background

    LY393558 is a combined antagonist of serotonin (5-HT) 5-HT 1B receptors and inhibitor of serotonin transporter (SERT). LY393558 reduces...

    Marta Baranowska-Kuczko, Hanna Kozłowska, ... Barbara Malinowska in Pharmacological Reports
    Article Open access 24 April 2020
  19. Phytoestrogenic Potential of Resveratrol by Selective Activation of Estrogen Receptor-α in Osteoblast Cells

    Resveratrol obtained in grape seed and skin is structurally similar to a synthetic estrogen diethylstilbestrol. The endogenous estrogen,...

    Aarti Abhishek Shah, Abhishek Shah, ... Yogendra Nayak in Revista Brasileira de Farmacognosia
    Article Open access 17 March 2022
  20. Metabolic and cardiovascular benefits and risks of 4-hydroxy guanabenz hydrochloride: α2-adrenoceptor and trace amine-associated receptor 1 ligand

    Background

    α 2 -adrenoceptor ligands have been investigated as potential therapeutic agents for the treatment of obesity. Our previous studies have...

    Magdalena Kotańska, Monika Marcinkowska, ... Marcin Kołaczkowski in Pharmacological Reports
    Article Open access 25 August 2023
Did you find what you were looking for? Share feedback.